DYSPLASIA DIAGNOSTICS LIMITED

Company Registration Number:
14361617 (England and Wales)

Unaudited abridged accounts for the year ended 30 September 2025

Period of accounts

Start date: 01 October 2024

End date: 30 September 2025

DYSPLASIA DIAGNOSTICS LIMITED

Contents of the Financial Statements

for the Period Ended 30 September 2025

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8
Balance sheet notes - 11

DYSPLASIA DIAGNOSTICS LIMITED

Company Information

for the Period Ended 30 September 2025




Director: Denise Williams
Dr Osagie Izuogu
Natalya VILYAVINA
Registered office: 85
Great Portland Street
London
England
W1W 7LT
Company Registration Number: 14361617 (England and Wales)

DYSPLASIA DIAGNOSTICS LIMITED

Directors' Report Period Ended 30 September 2025

The directors present their report with the financial statements of the company for the period ended 30 September 2025

Principal Activities

The company's principal activity during this period was Biotech Research and Development

Directors

The directors shown below have held office during the whole of the period from 01 October 2024 to 30 September 2025
Denise Williams
Dr Osagie Izuogu

The director(s) shown below were appointed to the company during the period
Natalya VILYAVINA
07 November 2024

The director(s) shown below resigned during the period
Natalya VILYAVINA
17 February 2025

This report was approved by the board of directors on 10 November 2025
And Signed On Behalf Of The Board By:

Name: Denise Williams
Status: Director

DYSPLASIA DIAGNOSTICS LIMITED

Profit and Loss Account

for the Period Ended 30 September 2025


Notes

2025
£

2024
£
Gross Profit or (Loss) ( 33,757 ) ( 9,950 )
Operating Profit or (Loss) ( 33,757 ) ( 9,950 )
Profit or (Loss) Before Tax ( 33,757 ) ( 9,950 )
Profit or (Loss) for Period ( 33,757 ) ( 9,950 )

The notes form part of these financial statements

DYSPLASIA DIAGNOSTICS LIMITED

Balance sheet

As at 30 September 2025


Notes

2025
£

2024
£
Fixed assets
Tangible assets: 4 210 340
Total fixed assets: 210 340
Current assets
Debtors: 2,341 236
Cash at bank and in hand: 1,582 619
Total current assets: 3,923 855
Creditors: amounts falling due within one year: ( 74,870 ) ( 38,174 )
Net current assets (liabilities): ( 70,947 ) ( 37,319 )
Total assets less current liabilities: ( 70,737 ) ( 36,979 )
Total net assets (liabilities): ( 70,737 ) ( 36,979 )

The notes form part of these financial statements

DYSPLASIA DIAGNOSTICS LIMITED

Balance sheet continued

As at 30 September 2025


Notes

2025
£

2024
£
Capital and reserves
Called up share capital: 100 100
Profit and loss account: ( 70,837 ) ( 37,079 )
Shareholders funds: ( 70,737 ) ( 36,979 )

For the year ending 30 September 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 10 November 2025
And Signed On Behalf Of The Board By:

Name: Denise Williams
Status: Director

The notes form part of these financial statements

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2025

  • 2. Employees


    2025

    2024
    Average number of employees during the period 5 3

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2025

  • 3. Off balance sheet disclosure

    No

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2025

4. Tangible Assets

Total
Cost £
At 01 October 2024 1,020
Additions -
Disposals -
Revaluations -
Transfers -
At 30 September 2025 1,020
Depreciation
At 01 October 2024 680
Charge for year 130
On disposals -
Other adjustments -
At 30 September 2025 810
Net book value
At 30 September 2025 210
At 30 September 2024 340

DYSPLASIA DIAGNOSTICS LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2025

  • 5. Financial Commitments

    Going concern

    The company incurred net liabilities of £70,737 as at 30 September 2025. Nevertheless, the directors have assessed the company's ability to continue as a going concern for a period of at least twelve months from the date of approval of these financial statements. The directors and shareholders have confirmed they will not demand repayment of their loans within this period and will provide such further financial support as is necessary to enable the company to meet its liabilities as they fall due. In preparing cash-flow forecasts, the directors have also considered non-cash cloud compute credits available to the company. As at the date of approval, unused credits of approximately £160,000 remain; these credits are non-transferable, non-refundable, and can only be applied to eligible cloud usage, expiring between June 2026 and June 2027. The credits reduce forecast cash outflows for infrastructure costs but do not give rise to an asset (and are not government grants) and are therefore not recognised in these financial statements; instead, they will reduce cloud expenses when utilised. Having regard to these factors, the directors consider the going-concern basis of preparation to be appropriate.